{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:09Z","timestamp":1794565329510,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ygyno.2026.05.023","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:40:15Z","timestamp":1780501215000},"page":"140-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours"],"prefix":"10.1016","volume":"210","author":[{"given":"Tuana","family":"Haznedar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Durante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Clobiaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2026.05.023_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.023_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/er.2011-0014","article-title":"Molecular pathogenesis of granulosa cell tumors of the ovary","volume":"33","author":"Jamieson","year":"2012","journal-title":"Endocr. Rev."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2026.05.023_bb0015","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.023_bb0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IGC.0000000000000304","article-title":"Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience","volume":"25","author":"Bryk","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2026.05.023_bb0025","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/aogs.14189","article-title":"Progress in the management of ovarian granulosa cell tumor: a review","volume":"100","author":"Li","year":"2021","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2026.05.023_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gore.2016.03.005","article-title":"Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy for recurrent adult granulosa cell tumor: a case report","volume":"16","author":"Dogan","year":"2016","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.05.023_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijscr.2015.05.004","article-title":"A recurrent granulosa cell tumor of the ovary 25 years after the initial diagnosis: a case report","volume":"12","author":"Fujita","year":"2015","journal-title":"Int. J. Surg. Case Rep."},{"key":"10.1016\/j.ygyno.2026.05.023_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13048-020-00619-6","article-title":"Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Ovarian Res."},{"issue":"10185","key":"10.1016\/j.ygyno.2026.05.023_bb0045","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.05.023_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2023.05.014","article-title":"Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salom\u00e9 study including 469 patients. A TMRG and GINECO group study","volume":"174","author":"Hanvic","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.023_bb0055","article-title":"Recurrent granulosa cell tumor in a postmenopausal woman: a case report and literature review","volume":"15","author":"Dolkar","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.ygyno.2026.05.023_bb0060","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/cancers14122998","article-title":"Response to systemic therapies in ovarian adult granulosa cell tumors: a literature review","volume":"14","author":"Brink","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/IGC.0000000000000882","article-title":"High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for blood and marrow transplantation","volume":"27","author":"De Giorgi","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.023_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2014.12.026","article-title":"The role of systemic chemotherapy in the management of granulosa cell tumors","volume":"136","author":"Meisel","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.05.023_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.49685","article-title":"Stereotactic body radiotherapy without systemic therapy for oligometastatic cancer: a systematic review and meta-analysis","volume":"8","author":"Willmann","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ygyno.2026.05.023_bb0080","article-title":"SBRT in recurrent oligometastatic ovarian cancer: an EORTC Y-ECI GCG systematic review","volume":"53","author":"Huck","year":"2025","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.023_bb0085","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijrobp.2009.12.005","article-title":"Role of adjuvant radiotherapy in granulosa cell tumors of the ovary","volume":"79","author":"Hauspy","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0090","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.023_bb0095","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian Cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7624","key":"10.1016\/j.ygyno.2026.05.023_bb0100","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.ygyno.2026.05.023_bb0110","author":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0115","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1120\/jacmp.v15i2.4685","article-title":"Commissioning and initial stereotactic ablative radiotherapy experience with Vero","volume":"15","author":"Solberg","year":"2014","journal-title":"J. Appl. Clin. Med. Phys."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.meddos.2007.01.009","article-title":"Trilogy image-guided stereotactic radiosurgery","volume":"32","author":"Huntzinger","year":"2007","journal-title":"Med. Dosim."},{"issue":"7","key":"10.1016\/j.ygyno.2026.05.023_bb0125","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/02841860600897942","article-title":"Tomotherapeutic stereotactic body radiation therapy: techniques and comparison between modalities","volume":"45","author":"Fuss","year":"2006","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ygyno.2026.05.023_bb0130","article-title":"Oligometastatic granulosa cell tumor treated with stereotactic body radiation therapy with a radiographic and tumor marker response","volume":"58","author":"Petty","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0135","article-title":"Radiographic and tumor biomarker response to radiotherapy for recurrent granulosa cell tumor of the ovary","volume":"13","author":"Singh","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.023_bb0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2006.02.034","article-title":"Palliative radiotherapy for recurrent granulosa cell tumor of the ovary: a report of 3 cases with radiological evidence of response","volume":"102","author":"Choan","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.023_bb0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12672-022-00540-y","article-title":"Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment","volume":"13","author":"Shen","year":"2022","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.023_bb0150","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3\/RAD phase II trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.023_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2025.03.032","article-title":"Treatment of oligometastatic parenchymal lesions in ovarian Cancer with stereotactic ablative radiation therapy: a Multicenter prospective phase 2 trial (MITO RT3\/RAD)","volume":"123","author":"Macchia","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.ygyno.2026.05.023_bb0160","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ijgc-2020-002205","article-title":"Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients","volume":"31","author":"Portuesi","year":"2021","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:20:42Z","timestamp":1794561642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S0090825826020007"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}